Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Virios Therapeutics, Inc. VIRI
$1.10
+$0.03 (2.79%)
На 18:03, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
17910634.00000000
-
week52high
9.11
-
week52low
0.22
-
Revenue
0
-
P/E TTM
-2
-
Beta
1.92873000
-
EPS
-1.24000000
-
Last Dividend
0.00000000
-
Next Earnings Date
12 авг 2021 г. в 12:30
Описание компании
Virios Therapeutics, Inc., a development-stage biotechnology company, focuses on developing antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It is also developing IMC-2, a combination of valacyclovir and celecoxib for the treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with long COVID. The company was formerly known as Virios Therapeutics, LLC and changed its name to Virios Therapeutics, Inc. in December 2020. Virios Therapeutics, Inc. was founded in 2012 and is headquartered in Alpharetta, Georgia.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| HC Wainwright & Co. | Buy | 15 дек 2021 г. | |
| HC Wainwright & Co. | Neutral | Buy | 20 сент 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Duncan Gregory Scott | A | 480000 | 480000 | 12 дек 2022 г. |
| Gendreau Roger Michael | A | 80000 | 80000 | 12 дек 2022 г. |
| Grosswald Ralph | A | 80000 | 80000 | 12 дек 2022 г. |
| Walsh Angela | A | 80000 | 80000 | 12 дек 2022 г. |
| Whitley Richard James | D | 700 | 1800 | 08 дек 2022 г. |
| Whitley Richard James | A | 5250 | 5250 | 23 июн 2022 г. |
| Pridgen William | A | 5250 | 5250 | 23 июн 2022 г. |
| Burch Richard Alan | A | 5250 | 5250 | 23 июн 2022 г. |
| Keefer David R | A | 5250 | 5250 | 23 июн 2022 г. |
| Thomas John C | A | 5250 | 5250 | 23 июн 2022 г. |
Новостная лента
Penny Stocks To Buy? 3 Stocks Under $1 To Watch Now
PennyStocks
05 янв 2023 г. в 14:39
Penny stocks under $1 to watch this month. The post Penny Stocks To Buy?
Virios Therapeutics, Inc. to Present at the Virtual Planet MicroCap Showcase
Business Wire
29 ноя 2022 г. в 07:05
ATLANTA--( BUSINESS WIRE )--Virios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, including fibromyalgia, today announced that Greg Duncan, Chairman and CEO of Virios Therapeutics will be attending and presenting at the Planet MicroCap Showcase, which is taking place virtually December 6 – 8, 2022.
Virios Therapeutics, Inc. (VIRI) CEO Greg Duncan on Q3 2022 Results - Earnings Call Transcript
Seeking Alpha
14 ноя 2022 г. в 14:37
Virios Therapeutics, Inc. (NASDAQ:VIRI ) Q3 2022 Earnings Conference Call November 14, 2022 8:30 AM ET Company Participants Greg Duncan - CEO Ralph Grosswald - SVP, Operations Angela Walsh - SVP, Finance & Treasurer Dr. Mike Gendreau - Chief Medical Officer Conference Call Participants Sean Lee - H.C. Wainwright & Co., LLC Operator Good day, and welcome to the Virios Therapeutics, Inc. Q3 Earnings Update.
Virios Therapeutics to Report Third Quarter 2022 Financial Results and Provide Corporate Update on Monday, November 14, 2022
Business Wire
03 ноя 2022 г. в 07:05
ATLANTA--(BUSINESS WIRE)---- $VIRI #Biotech--Virios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, including fibromyalgia, announced today that its third quarter 2022 financial results will be reported on Monday, November 14, 2022 before the open of the financial markets.
These Were the Five Best and Worst Performing Healthcare Stocks in Q3 2022
24/7 Wall Street
24 окт 2022 г. в 21:21
The healthcare industry is now starting to shift its focus away from the coronavirus pandemic to work on its core activities.